In Future CRISPR Gene Editing To Treat Diseases, Says Intellia Co-Founder: CNBC
Gene-editing technology CRISPR reached a significant milestone this week, completing its first systemic delivery as a medicine to the human body.
EC Selects Antibody Therapies, Arthritis Drug As Preferred COVID-19 Meds: Reuters
The European Commission (EC) picked four antibody treatments and a repurposed Eli Lilly And Co’s (NYSE:LLY) rheumatoid arthritis drug for an initial…
Why Regeneron Pharmaceuticals Analyst Says Competitive Concerns Are Overblown, Pipeline Opportunity Underappreciated
Regeneron Pharmaceuticals Inc.'s (NASDAQ: REGN) robust pipeline and attractive valuation has prompted an analyst at HC Wainwright to join the bullish camp.
Is Now The Time To Buy Stock In Tesla, GM Or Regeneron?
One of the most common questions traders have about stocks is “Why Is It Moving?”
That’s why Benzinga created the Why Is It Moving, or WIIM, feature in Benzinga Pro. WIIMs are a one-sentence description as to why that stock is moving.
Intellia Seeks To Raise $400M Via Equity
Intellia Therapeutics Inc (NASDAQ:NTLA) commenced an underwritten public offering of $400 million shares of its common stock. Underwriters have an option…
Benzinga Pro’s Top 5 Stocks To Watch For Monday, Jun. 28, 2021: CCL, NTLA, DDL, PRVB, WBA
Today's 5 Stock Ideas
Carnival (CCL) - Shares were down 2% following news the company registered an offering of $500 million in common stock for a shelf.
Intellia Therapeutics (NTLA) - The
Why Intellia Therapeutics Stock Is Soaring Today
Intellia Therapeutics Inc (NASDAQ: NTLA) is trading significantly higher Monday morning after the company announced positive clinical data for its CRISPR therapy.
Intellia Shares Shoot Higher On Promising Biomarker Data From CRISPR/Cas9 Genome Editing Candidate
Intellia Therapeutics Inc (NASDAQ:NTLA) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) have announced positive interim data from an ongoing Phase 1 study of NTLA-2001, which…
Regeneron’s and Sanofi’s Dupixent SmPC Updated With Long-term Data Reinforcing Well-established Safety Profile in Adults With Moderate-to-severe Atopic Dermatitis
Long-term safety data from a study of adults with moderate-to-severe atopic dermatitis treated with Dupixent will be added to the Dupixent Summary of Product Characteristics (SmPC) following a positive opinion issued by the European Medicines Agency's Committee for Medicinal Products for Human Use.